Intrexon Corporation

About Intrexon Corporation

Through the engineering of biology, Intrexon is helping to address some of the world’s most pressing challenges and is working with industry and government leaders to realize a better, healthier planet. Today our platform is delivering new therapies in health, supplying unique solutions to address global energy demand, developing unparalleled features and productivity advancements in food, creating innovative applications for consumers, and helping to restore and protect the environment.

To execute on its mission, Intrexon has integrated a suite of technologies and expertise across a number of cellular systems to drive development and commercialization of bio-based solutions. Our solutions include: Friendly™ Aedes mosquitoes genetically engineered to suppress the invasive Aedes aegypti mosquito; Arctic® apples that will not brown when bitten, sliced, or bruised; a clinically validated transcriptional gene switch to precisely control production of biotherapeutics; bovine reproductive technologies driving genetic gain for the dairy and beef industries; genetically engineered miniature swine models to provide better predictive efficacy in evaluation of new medicines; and our AquAdvantage® salmon bringing productivity benefits to the aquaculture industry through our majority-owned subsidiary AquaBounty. Intrexon’s cutting-edge platforms have broad applicability, thus opening the door to the considerable potential of engineered biology.

Intrexon and our collaborators are building solutions to challenging issues across fields as diverse as medicine, fuel, agriculture, nutrition, personal care, chemicals, and manufacturing, forging a sustainable path forward for current and future generations. We call our approach Better DNA® and invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook and LinkedIn.

Intrexon Corporation and its majority owned Intrexon Health subsidiary Xogenex, announced that four abstracts will be presented as posters at the American Society of Gene and Cell Therapy Annual Meeting, which will be held April 29 - May 2, 2019, at the Washington Hilton in Washington, D.C.

Intrexon Corporation, a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, announced it will release fourth quarter 2018 financial results after the market closes on Thursday, February 28th, 2019.

Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that the company and its subsidiaries will present at upcoming investor conferences in San Francisco.

Intrexon Corporation today announced it will release third quarter 2018 financial results after the market closes on Thursday, November 8th, 2018. The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update.